**Appendix Table D12. Reduction in migraine days with topiramate vs. placebo in children (pooled with random effects results from randomized controlled clinical trials)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference**  **Dose of topiramate** | **Outcome with drug**  **[Standard deviation]** | **Outcome with placebo**  **[Standard deviation]** | **Standardized mean difference**  **(95% CI)** | **Weight** | **Mean ratio**  **(95% CI)** | **Weight** | **Risk of bias** |
| Winner, 20058 50 mg/day at week 3, titrated to a max dose of 200 mg/day (2-3kg mg/kg/day) | -2.6 [2.6] | -2.0 [3.1] | -0.22 (-0.55 to 0.12) | 58.4 | 1.30 (0.81 to 2.08) | 35.41 | Medium |
| Lewis, 20097 25mg/day initially and then gradually increased to 100mg/day, dosed twice daily \* | -75.9 [32.42] | -49.7 [46.06] | -0.66 (-1.15 to -0.17) | 41.6 | **1.53 (1.08 to 2.16)** | 64.59 | Low |
| Pooled |  |  | -0.40 (-0.83 to 0.03) | 100 | **1.44 (1.09 to 1.91)** | 100 |  |
| Lewis, 20097 25mg/day initially and then gradually increased to 50mg/day, dosed twice daily at the investigator’s discretion | -52.5 [48.55] | -49.7 [46.06] | -0.06 (-0.54 to 0.42) | 100 | 1.06 (0.68 to 1.64) | 100 | Low |
| Pooled overall |  |  | -0.30 (-0.61 to 0.02) |  | **1.32 (1.04 to 1.67)** |  | Medium |
| Heterogeneity statistics |  |  | P value = 0.192  I squared = 39.4% |  | **P value = 0.434**  **I squared = 0%** |  |  |

Bold = significant difference at 95% confidence level when 95%CI of mean difference do not include 0; **\*-** at the investigator’s discretion the dose was increased to the maximal dose tolerated by the subjects, 91% achieved the target daily dose during the double-blind treatment phase, the daily dose used during the entire double-blind treatment phase (titration and maintenance) was 73.6 ±18.7 mg/day